|
注册号: Registration number: |
ChiCTR2400091242 |
|
最近更新日期: Date of Last Refreshed on: |
2024-10-23 17:29:44 |
|
注册时间: Date of Registration: |
2024-10-23 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
抑郁障碍患者的元认知结构及其代谢组学特征研究 |
|
Public title: |
Metacognitive structure and its metabolomic profile in patients with depressive disorders |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
抑郁障碍患者的元认知结构及其代谢组学特征研究 |
|
Scientific title: |
Metacognitive structure and its metabolomic profile in patients with depressive disorders |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
洪舒宁 |
研究负责人: |
陶明 |
|
Applicant: |
Shuning Hong |
Study leader: |
Ming Tao |
|
申请注册联系人电话: Applicant telephone: |
+86 151 5716 7337 |
研究负责人电话:
Study leader's |
+86 138 6807 2111 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hongshuning1215@163.com |
研究负责人电子邮件: Study leader's E-mail: |
taoming@21cn.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江省杭州市临安区同人山庄望庐13幢 |
研究负责人通讯地址: |
浙江省杭州市临安区同人山庄望庐13幢 |
|
Applicant address: |
Block 13, Wanglu, Tongren Villa, Lin'an District, Hangzhou, Zhejiang Province, China |
Study leader's address: |
Block 13, Wanglu, Tongren Villa, Lin'an District, Hangzhou, Zhejiang Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
浙江中医药大学 |
||
|
Applicant's institution: |
Zhejiang University of Chinese Medicine |
||
|
研究负责人所在单位: |
浙江中医药大学 |
||
|
Affiliation of the Leader: |
Zhejiang University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
研(2024年)伦审第(025)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
杭州市第七人民医院伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Review Committee of Hangzhou Seventh People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-04-09 00:00:00 | ||
|
伦理委员会联系人: |
张雨桐 |
||
|
Contact Name of the ethic committee: |
Yutong Zhang |
||
|
伦理委员会联系地址: |
浙江省杭州市天目山路305号 |
||
|
Contact Address of the ethic committee: |
No.305 Tianmushan Road, Hangzhou, Zhejiang, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 571 8512 3265 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
杭州市第七人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Hangzhou Seventh People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省杭州市天目山路305号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.305 Tianmushan Road, Hangzhou, Zhejiang, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
经费均来自导师课题经费(课题名称:抑郁障碍与帕金森病的交互“和”法疗效方案评价研究;课题编号:GZT-ZJ-KJ-23017) |
||||||||||||||||||||||
|
Source(s) of funding: |
Funding was provided by the mentor's project (Project name: Evaluation of the Interactive "Wo" Treatment Program for Depressive Disorders and Parkinson's Disease; Project number: GZT-ZJ-KJ-23017). |
||||||||||||||||||||||
|
研究疾病: |
抑郁障碍 |
||||||||||||||||||||||
|
Target disease: |
depressive disorder |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例对照研究 |
||||||||||||||||||||||
|
Study design: |
Case-Control study |
||||||||||||||||||||||
|
研究目的: |
(1)评估抑郁障碍患者的元认知结构及其与病情的相关性,探索其在抑郁障碍早期的诊断及预后判断的临床意义。 (2)探讨血清代谢产物(21种氨基酸、胆汁酸和脂肪酸的检测)与抑郁障碍的相关性。 (3)探究血清代谢产物(21种氨基酸、胆汁酸和脂肪酸的检测)与元认知结构的相关性。 (4)探索元认知结构与血清代谢组学变化对MDD的早期诊断以及预后判断的临床意义。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To assess the metacognitive structure of patients with depressive disorders and its correlation with the condition, and to explore its clinical significance in the diagnosis of early stages of depressive disorders and prognosis judgment. (2) To explore the correlation between serum metabolites (21 amino acids, bile acids and fatty acid tests) and depressive disorders. (3) To explore the correlation between serum metabolites (assays of 21 amino acids, bile acids and fatty acids) and metacognitive structure. (4) To explore the clinical significance of changes in metacognitive structure and serum metabolomics for early diagnosis of MDD as well as prognosis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1)孕妇或者是哺乳期妇女; (2)伴有精神病性症状的抑郁障碍患者,有自杀倾向的患者; (3)伴严重躯体疾病,例如严重肝肾疾病、心脏病、高血压、糖尿病、甲状腺疾病等。 (4)有精神活性物质滥用史或服用任何可能影响认知功能的药物(如糖皮质激素、β-受体阻滞剂、阿片类镇痛药和中枢兴奋剂)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Pregnant or lactating women; (2) Patients with depressive disorders accompanied by psychotic symptoms, patients with suicidal tendencies; (3) Patients with severe physical illnesses, such as severe liver or kidney disease, heart disease, hypertension, diabetes, thyroid disease, etc. (4) A history of psychoactive substance abuse or taking any medication that may affect cognitive function (e.g., glucocorticoids, beta-blockers, opioid analgesics, and central stimulants). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-01-01 00:00:00至 To 2025-04-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-04-15 00:00:00 至 To 2024-08-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
问卷星(链接)https://www.wjx.cn/vm/tU5a8m0.aspx |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Questionnaire Star (link) https://www.wjx.cn/vm/tU5a8m0.aspx |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |